- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Drotrecogin alfa (activated): real-life use and outcomes for the UK ; volume:12 ; number:2 ; day:22 ; month:04 ; year:2008 ; pages:1-12 ; date:4.2008
Critical care ; 12, Heft 2 (22.04.2008), 1-12, 4.2008
- Creator
-
Rowan, Kathryn M.
- Contributor
-
Welch, Catherine A.
North, Emma
Harrison, David A.
SpringerLink (Online service)
- DOI
-
10.1186/cc6879
- URN
-
urn:nbn:de:1111-2016080819407
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rowan, Kathryn M.
- Welch, Catherine A.
- North, Emma
- Harrison, David A.
- SpringerLink (Online service)
Other Objects (12)
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Cost-effectiveness of activated protein C in real-life clinical practice
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
Alfa
Alfa
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Real-life outcomes of subthreshold laser therapy for diabetic macular edema
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Original Alfa-Heu- und -Getreideaufzüge, Alfa-Sicherheitswinden
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
Long-term real-life outcomes of the Clareon® hydrophobic intraocular lens: the Clarte study in 191 eyes : 3-years real-life outcomes of the Clareon® intraocular lens
Häckseltrommel Alfa
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Cost-effectiveness of activated protein C in real-life clinical practice
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
Alfa
Alfa
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Real-life outcomes of subthreshold laser therapy for diabetic macular edema
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Original Alfa-Heu- und -Getreideaufzüge, Alfa-Sicherheitswinden
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
Long-term real-life outcomes of the Clareon® hydrophobic intraocular lens: the Clarte study in 191 eyes : 3-years real-life outcomes of the Clareon® intraocular lens
Häckseltrommel Alfa
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Cost-effectiveness of activated protein C in real-life clinical practice
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
Alfa
Alfa
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Real-life outcomes of subthreshold laser therapy for diabetic macular edema
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Original Alfa-Heu- und -Getreideaufzüge, Alfa-Sicherheitswinden
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
Long-term real-life outcomes of the Clareon® hydrophobic intraocular lens: the Clarte study in 191 eyes : 3-years real-life outcomes of the Clareon® intraocular lens